I'll let Minister Anand answer you. However, I first want to clarify one thing.
I can give you the example of Novavax and tell you exactly how the discussion went.
You must understand that we have very few manufacturing facilities in Quebec and in Canada that are suitable for the production of this type of vaccine. You'll say that we have GSK in Quebec City. However, GSK already manufactures the flu vaccine, so we don't want to disrupt that production. You'll say that we also have Sanofi, in Toronto. You're right, but Sanofi produces a vaccine against [Technical difficulty—Editor].
However, I can tell you what prompted Novavax to move forward. As I said, I had the opportunity to talk to the president and CEO of Novavax. The deciding factor was that the type of vaccine produced by the company is compatible with the production line at the NRC facilities in Montreal.
I'll now let Minister Anand respond.